4
Changes in Ownership
ARROWHEAD PHARMACEUTICALS, INC. Filed Acc 0001628280-24-052267
Chief Executive Officer sold 26,712 shares at an average $21.24 ($567,486)
- Chief Executive Officer acquired 100,000 shares (grant or award)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Anzalone Christopher Richard Chief Executive Officer | 2024-12-18 | Sale 10b5-1 | −12,653 | $20.52 | $259,640 | 3,702,394 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2024-12-18 | Sale 10b5-1 | −8,260 | $21.74 | $179,572 | 3,694,134 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2024-12-18 | Sale 10b5-1 | −5,799 | $22.12 | $128,274 | 3,688,335 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2024-12-18 | Grant or award 10b5-1 | +100,000 | 3,788,335 | D | ||
| Open-market sales · 26,712 sh · avg $21.24 · $567,486 | |||||||
Loading xslF345X05/wk-form4_1734735860.xml…